May 7, 2024

The Japan Kidney Association and Renalys Pharma Form Collaborative Agreement to Overcome Kidney Disease

The Japan Kidney Association and Renalys Pharma Form Collaborative Agreement to Overcome Kidney Disease

The Japan Kidney Association, a nonprofit organization, (Headquarters: Bunkyo-ku, Tokyo; “Japan Kidney Association”) and Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys Pharma”) entered into a collaborative agreement on May 1, 2024, with the aim to develop innovative therapies and raise the awareness to overcome kidney disease.

“Kidney disease is increasing against a background of changing lifestyles and an ageing population. Kidney disease is also associated with stroke, heart disease and cognitive impairment, and overcoming kidney disease is a priority issue in Japan because kidney disease is one of factors that undermines the healthy life expectancy of the population.” said Naoki Kashihara, MD, PhD, President of Japan Kidney Association. “Meanwhile, the number of unapproved drugs in Japan for drugs approved in Europe and the US has been increasing in recent years, called ‘drug loss’, which limits treatment options in Japan, is a major social issue. These are issues that need to be tackled in cooperation with the relevant stakeholders to help patients live their precious and irreplaceable lives. We hope that this agreement will be an opportunity for both parties to work together to achieve the common goal of overcoming kidney disease.”

“We are delighted to enter into this agreement with the Japan Kidney Association.” said BT Slingsby, MD, PhD, MPH, CEO of Renalys Pharma. “Renalys Pharma’s mission is to deliver better healthcare to kidney disease patients in Japan and other Asian countries by acting as a catalyst to access new treatments to address the growing problem of ‘drug loss’. Through the development of innovative therapies and activities to raise awareness of kidney disease, we will work together with the Japan Kidney Association to overcome kidney disease along with supporting people living their precious and desperate lives.”


About the Japan Kidney Association

The Japan Kidney Association is an organization established to overcome kidney disease through collaboration between medical professionals, citizens, related companies, government, and others. The association is actively raising public awareness of kidney disease, building a system for cooperation in medical treatment, operating a certified educators for kidney disease system, cooperating with patient associations, and operating the Kidney Research Initiative-Japan (KRI-J), a platform for cooperation between academia, related companies, government, and other organizations. The Japan Kidney Association is committed to realizing an environment in which people everywhere in Japan can get the benefits of high-quality medical care in the field of kidney care. For more information about the Kidney Research-Japan, please visit


About Renalys Pharma, Inc.
Renalys Pharma is a private, late-stage clinical biopharmaceutical company in Japan committed to the development of multiple innovative therapeutics that address unmet needs in the management of renal disease for Japanese and Asian patients. The company was established by Catalys Pacific and SR One to address the growing problem of “drug loss” by catalyzing an access to new treatments for kidney disease patients in Japan and other Asian territories.


Company Name: Renalys Pharma, Inc.
Address: 3-11, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, Japan
Representative: BT Slingsby, MD, PhD, MPH

Established: April 2023




Information concerning pharmaceutical products (compound under development) contained herein is not intended as advertising or as medical advice, but intended for disclosure of management information.


[Media Contact]

Renalys Pharma Communications Office (within Cosmo Publication Relations Corporation)


Japan Kidney Association Office